First patient included in HEPAR Primary study; treating hepatocellular carcinoma with QuiremSpheres®
On 15 December 2017, the first patient was included in the HEPAR Primary study by Dr. Arthur J.A.T. Braat at UMC Utrecht, the Netherlands. The patient, who is suffering from advanced stage hepatocellular carcinoma (HCC), will be treated with selective internal radiation therapy (SIRT) with QuiremSpheres®, presumably in January 2018. The HEPAR Primary study is to confirm safety and efficacy for treatment of advanced unresectable HCC using QuiremSpheres® (holmium-166 microspheres) in an estimated cohort of 30 patients. Current treatment options for the targeted patient group are limited. The standard-of-care treatment based on yttrium-90 has inherent limitations in image guidance and intraoperative depiction, whereas holmium-166 SIRT offers the potential for a more personal and quantitative approach. The HEPAR Primary study is an early phase II, multicenter, non-randomized, non-open label, non-comparative, treatment and interventional clinical trial. The Principe Investigator of this study is Prof. M.G.E Lam and the study is a collaboration between the UMC Utrecht and the Erasmus MC in Rotterdam. The study is expected to be completed in 2020. For details of this study, please click here. The successful inclusion of the first patient marks the beginning of this exciting study.